Skip to main content
. 2023 Apr 17;29(4):950–962. doi: 10.1038/s41591-023-02268-w

Extended Data Fig. 7. Enrichment of PVS genes in targets of drugs validated in other indications (Genome for REPositioning drugs, using ATC codes).

Extended Data Fig. 7

We found a significant enrichment of BG-PVS genes in targets for antiinfectives for systemic use (ATC J01, OR = 252.4, P = 8.85×10−3), driven by CRHR1 (chr17q21.31), a target for telavancin (A, B); of note, CRHR1 antagonists were shown to attenuate blood brain barrier permeability, cortical vascular hyperpermeability and tight junction disruption. ATC indicates Anatomical Therapeutic Chemical classification.